Review



primary antibodies against prostate-specific antigen (psa  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology primary antibodies against prostate-specific antigen (psa
    Effects of IM176, phenformin, and metformin on the inhibition of AR, AR-V7, and prostate-specific antigen <t>(PSA)</t> expression. (a) LNCaP and 22Rv1 cells were treated with IC 50 concentrations of IM176 (20 μmol/L and 40 μmol/L, respectively), phenformin (40 μmol/L and 400 μmol/L, respectively), and metformin (4 mmol/L and 10 mmol/L, respectively) for 72 hours, and relative mRNA levels of AR and AR-V7 were quantified by real-time PCR. Each point represents the mean ± standard deviation of triplicate determinations. ∗p < 0.05 compared with untreated control. (b) LNCaP and 22Rv1 cells were treated with the indicated concentrations of IM176, phenformin, and metformin for 72 hours. Western blot analysis was performed <t>using</t> <t>antibodies</t> to AR, AR-V7, and PSA, with GAPDH used as a loading control. (c) LNCaP and 22Rv1 cells were treated for 72 hours with the IC 50 concentrations of IM176, phenformin, and metformin, as shown in (a), above. Samples were stained with antibody to AR (red) and the nuclear stain DAPI (blue). Images were captured on a fluorescence microscope. Scale bar, 50 μM. AR, androgen receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mRNA, messenger RNA; PCR, polymerase chain reaction.
    Primary Antibodies Against Prostate Specific Antigen (Psa, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against prostate-specific antigen (psa/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against prostate-specific antigen (psa - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways"

    Article Title: A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways

    Journal: Prostate International

    doi: 10.1016/j.prnil.2022.11.003

    Effects of IM176, phenformin, and metformin on the inhibition of AR, AR-V7, and prostate-specific antigen (PSA) expression. (a) LNCaP and 22Rv1 cells were treated with IC 50 concentrations of IM176 (20 μmol/L and 40 μmol/L, respectively), phenformin (40 μmol/L and 400 μmol/L, respectively), and metformin (4 mmol/L and 10 mmol/L, respectively) for 72 hours, and relative mRNA levels of AR and AR-V7 were quantified by real-time PCR. Each point represents the mean ± standard deviation of triplicate determinations. ∗p < 0.05 compared with untreated control. (b) LNCaP and 22Rv1 cells were treated with the indicated concentrations of IM176, phenformin, and metformin for 72 hours. Western blot analysis was performed using antibodies to AR, AR-V7, and PSA, with GAPDH used as a loading control. (c) LNCaP and 22Rv1 cells were treated for 72 hours with the IC 50 concentrations of IM176, phenformin, and metformin, as shown in (a), above. Samples were stained with antibody to AR (red) and the nuclear stain DAPI (blue). Images were captured on a fluorescence microscope. Scale bar, 50 μM. AR, androgen receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mRNA, messenger RNA; PCR, polymerase chain reaction.
    Figure Legend Snippet: Effects of IM176, phenformin, and metformin on the inhibition of AR, AR-V7, and prostate-specific antigen (PSA) expression. (a) LNCaP and 22Rv1 cells were treated with IC 50 concentrations of IM176 (20 μmol/L and 40 μmol/L, respectively), phenformin (40 μmol/L and 400 μmol/L, respectively), and metformin (4 mmol/L and 10 mmol/L, respectively) for 72 hours, and relative mRNA levels of AR and AR-V7 were quantified by real-time PCR. Each point represents the mean ± standard deviation of triplicate determinations. ∗p < 0.05 compared with untreated control. (b) LNCaP and 22Rv1 cells were treated with the indicated concentrations of IM176, phenformin, and metformin for 72 hours. Western blot analysis was performed using antibodies to AR, AR-V7, and PSA, with GAPDH used as a loading control. (c) LNCaP and 22Rv1 cells were treated for 72 hours with the IC 50 concentrations of IM176, phenformin, and metformin, as shown in (a), above. Samples were stained with antibody to AR (red) and the nuclear stain DAPI (blue). Images were captured on a fluorescence microscope. Scale bar, 50 μM. AR, androgen receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mRNA, messenger RNA; PCR, polymerase chain reaction.

    Techniques Used: Inhibition, Expressing, Real-time Polymerase Chain Reaction, Standard Deviation, Control, Western Blot, Staining, Fluorescence, Microscopy, Polymerase Chain Reaction



    Similar Products

    primary antibody against psa  (Boster Bio)
    92
    Boster Bio primary antibody against psa
    Primary Antibody Against Psa, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody against psa/product/Boster Bio
    Average 92 stars, based on 1 article reviews
    primary antibody against psa - by Bioz Stars, 2026-05
    92/100 stars
    		  Buy from Supplier
    primary antibodies against prostate-specific antigen (psa  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology primary antibodies against prostate-specific antigen (psa
    Effects of IM176, phenformin, and metformin on the inhibition of AR, AR-V7, and prostate-specific antigen <t>(PSA)</t> expression. (a) LNCaP and 22Rv1 cells were treated with IC 50 concentrations of IM176 (20 μmol/L and 40 μmol/L, respectively), phenformin (40 μmol/L and 400 μmol/L, respectively), and metformin (4 mmol/L and 10 mmol/L, respectively) for 72 hours, and relative mRNA levels of AR and AR-V7 were quantified by real-time PCR. Each point represents the mean ± standard deviation of triplicate determinations. ∗p < 0.05 compared with untreated control. (b) LNCaP and 22Rv1 cells were treated with the indicated concentrations of IM176, phenformin, and metformin for 72 hours. Western blot analysis was performed <t>using</t> <t>antibodies</t> to AR, AR-V7, and PSA, with GAPDH used as a loading control. (c) LNCaP and 22Rv1 cells were treated for 72 hours with the IC 50 concentrations of IM176, phenformin, and metformin, as shown in (a), above. Samples were stained with antibody to AR (red) and the nuclear stain DAPI (blue). Images were captured on a fluorescence microscope. Scale bar, 50 μM. AR, androgen receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mRNA, messenger RNA; PCR, polymerase chain reaction.
    Primary Antibodies Against Prostate Specific Antigen (Psa, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against prostate-specific antigen (psa/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against prostate-specific antigen (psa - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Effects of IM176, phenformin, and metformin on the inhibition of AR, AR-V7, and prostate-specific antigen (PSA) expression. (a) LNCaP and 22Rv1 cells were treated with IC 50 concentrations of IM176 (20 μmol/L and 40 μmol/L, respectively), phenformin (40 μmol/L and 400 μmol/L, respectively), and metformin (4 mmol/L and 10 mmol/L, respectively) for 72 hours, and relative mRNA levels of AR and AR-V7 were quantified by real-time PCR. Each point represents the mean ± standard deviation of triplicate determinations. ∗p < 0.05 compared with untreated control. (b) LNCaP and 22Rv1 cells were treated with the indicated concentrations of IM176, phenformin, and metformin for 72 hours. Western blot analysis was performed using antibodies to AR, AR-V7, and PSA, with GAPDH used as a loading control. (c) LNCaP and 22Rv1 cells were treated for 72 hours with the IC 50 concentrations of IM176, phenformin, and metformin, as shown in (a), above. Samples were stained with antibody to AR (red) and the nuclear stain DAPI (blue). Images were captured on a fluorescence microscope. Scale bar, 50 μM. AR, androgen receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mRNA, messenger RNA; PCR, polymerase chain reaction.

    Journal: Prostate International

    Article Title: A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways

    doi: 10.1016/j.prnil.2022.11.003

    Figure Lengend Snippet: Effects of IM176, phenformin, and metformin on the inhibition of AR, AR-V7, and prostate-specific antigen (PSA) expression. (a) LNCaP and 22Rv1 cells were treated with IC 50 concentrations of IM176 (20 μmol/L and 40 μmol/L, respectively), phenformin (40 μmol/L and 400 μmol/L, respectively), and metformin (4 mmol/L and 10 mmol/L, respectively) for 72 hours, and relative mRNA levels of AR and AR-V7 were quantified by real-time PCR. Each point represents the mean ± standard deviation of triplicate determinations. ∗p < 0.05 compared with untreated control. (b) LNCaP and 22Rv1 cells were treated with the indicated concentrations of IM176, phenformin, and metformin for 72 hours. Western blot analysis was performed using antibodies to AR, AR-V7, and PSA, with GAPDH used as a loading control. (c) LNCaP and 22Rv1 cells were treated for 72 hours with the IC 50 concentrations of IM176, phenformin, and metformin, as shown in (a), above. Samples were stained with antibody to AR (red) and the nuclear stain DAPI (blue). Images were captured on a fluorescence microscope. Scale bar, 50 μM. AR, androgen receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mRNA, messenger RNA; PCR, polymerase chain reaction.

    Article Snippet: Primary antibodies against phosphor-AMPK threonine 172 (pAMPK), AMPK, phospho-mTOR serine 2448 (pmTOR), mTOR, phospho-p70S6 kinase 1 threonine 389 (pp70S6K1), p70S6K1, phospho-S6 serine 235/236 (pS6), S6 caspase-3, and poly (ADP-ribose) polymerase were obtained from Cell Signaling Technology (Danvers, MA, USA); primary antibodies against AR, prostate-specific antigen (PSA), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were from Santa Cruz Biotechnology (Dallas, TX, USA), and primary antibody against AR-V7 was from Precision Antibody (Columbia, MD, USA).

    Techniques: Inhibition, Expressing, Real-time Polymerase Chain Reaction, Standard Deviation, Control, Western Blot, Staining, Fluorescence, Microscopy, Polymerase Chain Reaction